Merck names Cressey managing partner Paul Diaz to board effective Nov. 1, 2026

Merck appointed Paul J. Diaz, managing partner at Cressey & Company, to its board effective Nov. 1, 2026. Diaz previously served as CEO of Myriad Genetics, leading genetic testing and precision medicine, earlier running Kindred Healthcare. Board size will increase to 14 directors; Diaz is set to stand for election at the May 2027 annual meeting. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Merck & Co. Inc. published the original content used to generate this news brief via (Ref. ID: 202610130702BIZWIRE_USPR_____20261013_BW226953) on October 13, 2026, and is solely responsible for the information contained therein. (C)